Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Haematology"
DOI: 10.1111/ejh.13492
Abstract: Venetoclax combined with hypomethylating agents is a new therapeutic strategy frequently used for treating AML patients who are not eligible for conventional chemotherapy. However, high response rates are heterogeneous due to different mechanisms mediating resistance… read more here.
Keywords: inhibition venetoclax; improves therapeutic; venetoclax; mcl inhibition ... See more keywords
Evaluation of combined BCL-2/MCL-1 inhibition as a therapeutic approach for synovial sarcoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e23561
Abstract: e23561Background: While Synovial Sarcoma (SS) only accounts for about 10% of soft tissue sarcomas (STS), or ~10,000 cases/year, ~4,000 of these will be fatal. Little benefit has been seen with newe... read more here.
Keywords: sarcoma; evaluation combined; mcl inhibition; combined bcl ... See more keywords